Nektar Therapeutics (NKTR) Receives Consensus Recommendation of “Buy” from Analysts

Nektar Therapeutics (NASDAQ:NKTR) has been given a consensus recommendation of “Buy” by the sixteen analysts that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $48.18.

A number of analysts have recently commented on the company. BidaskClub cut Nektar Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 8th. Mizuho reissued a “buy” rating and issued a $89.00 price target on shares of Nektar Therapeutics in a research report on Wednesday, February 14th. Zacks Investment Research raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Jefferies Group boosted their price target on Nektar Therapeutics from $2.12 to $88.00 and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $80.00 price target (up from $50.00) on shares of Nektar Therapeutics in a research report on Wednesday, January 10th.

Shares of Nektar Therapeutics (NKTR) opened at $83.45 on Wednesday. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99. Nektar Therapeutics has a 12-month low of $12.50 and a 12-month high of $99.02. The company has a market capitalization of $13,381.02, a P/E ratio of -115.90 and a beta of 2.04.

In related news, SVP Stephen K. Doberstein sold 2,426 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $82.94, for a total value of $201,212.44. Following the transaction, the senior vice president now directly owns 67,394 shares of the company’s stock, valued at approximately $5,589,658.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Howard W. Robin sold 83,333 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $55.69, for a total value of $4,640,814.77. Following the completion of the transaction, the chief executive officer now directly owns 272,768 shares in the company, valued at $15,190,449.92. The disclosure for this sale can be found here. Insiders sold a total of 222,781 shares of company stock worth $14,884,901 over the last ninety days. 5.44% of the stock is currently owned by insiders.

Hedge funds have recently added to or reduced their stakes in the stock. BB&T Investment Services Inc. bought a new position in Nektar Therapeutics in the 4th quarter valued at approximately $119,000. Meeder Asset Management Inc. bought a new position in Nektar Therapeutics in the 4th quarter valued at approximately $121,000. Oppenheimer Asset Management Inc. bought a new position in Nektar Therapeutics in the 3rd quarter valued at approximately $129,000. Mark Sheptoff Financial Planning LLC lifted its position in Nektar Therapeutics by 79.4% in the 3rd quarter. Mark Sheptoff Financial Planning LLC now owns 6,100 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 2,700 shares in the last quarter. Finally, SeaCrest Wealth Management LLC bought a new position in Nektar Therapeutics in the 4th quarter valued at approximately $200,000. 96.23% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This article was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://ledgergazette.com/2018/02/21/nektar-therapeutics-nktr-receives-consensus-recommendation-of-buy-from-analysts.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply